Jyong Biotech Ltd. (MENS) Balance Sheet
MENS balance sheet, 2025
December 31, 2025 · U.S. dollars$20.8M assets = $45.7M liabilities + −$24.9M equity
Liabilities exceed assets: shareholders’ equity is negative (−$24.9M).
Both columns are drawn to the same scale: what MENS owns equals what it owes plus shareholders’ equity. Hover a block for its value.
MENS financial health
Descriptive bands, not a rating. Fiscal 2025.
MENS balance sheet trends, 2020–2025
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Total assets | $12.8M2020 | $20.8M2025 | +10.1%/yr | |
| Total liabilities | $32.0M2020 | $45.7M2025 | +7.3%/yr | |
| Shareholders’ equity | −$19.2M2020 | −$24.9M2025 | — | |
| Cash & short-term investments | $4.2M2020 | $1.2M2025 | −22.5%/yr | |
| Total debt | $13.6M2020 | $18.5M2025 | +6.4%/yr | |
| Net cash (debt) | −$9.4M2020 | −$17.4M2025 | −$8.0M | |
| Working capital | $443,0002020 | −$19.3M2025 | −$19.7M | |
| Book value per share | −$0.272020 | −$0.342025 | — | |
| Current ratio | 1.082020 | 0.452025 | −0.63 | |
| Shares outstanding | 71.6M2020 | 73.0M2025 | +0.4%/yr |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
MENS assets
MENS liabilities and equity
MENS debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease obligations.
MENS balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Assets | ||||||
| Cash & short-term investments | $1.2M | $98,000 | $177,000 | $812,000 | $2.4M | $4.2M |
| Cash & equivalents | $1.2M | $98,000 | $177,000 | $718,000 | $551,000 | $3.6M |
| Short-term investments | — | — | $0 | $94,000 | $1.8M | $664,000 |
| Receivables | $13.5M | $0 | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 |
| Other current assets | $854,000 | $108,000 | $1.7M | $1.7M | $263,000 | $2.0M |
| Total current assets | $15.5M | $206,000 | $1.8M | $2.5M | $2.6M | $6.2M |
| Property, plant & equipment (net) | $5.2M | $3.2M | $3.5M | $6.0M | $6.8M | $6.6M |
| Goodwill & intangible assets | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-term investments | $0 | $0 | $0 | $0 | $0 | $0 |
| Other non-current assets | $6,000 | $3.0M | $2.9M | $283,000 | $8,000 | $10,000 |
| Total assets | $20.8M | $6.4M | $8.2M | $8.7M | $9.4M | $12.8M |
| Liabilities | ||||||
| Accounts payable | $2,000 | $3,000 | $2,000 | $4,000 | $46,000 | $25,000 |
| Short-term debt | $8.4M | $7.4M | $8.1M | $7.8M | $5.2M | $5.0M |
| Total current liabilities | $34.8M | $12.1M | $14.3M | $12.9M | $6.3M | $5.8M |
| Long-term debt | $10.2M | $10.7M | $8.5M | $6.3M | $6.3M | $0 |
| Lease obligations | $107,000 | $175,000 | $199,000 | $285,000 | $596,000 | — |
| Other long-term liabilities | $713,999 | $20.1M | $19.5M | $19.2M | $20.2M | $26.3M |
| Total liabilities | $45.7M | $42.9M | $42.3M | $38.4M | $32.8M | $32.0M |
| Shareholders' equity | ||||||
| Common stock & paid-in capital | $1,000 | $1,000 | $1,000 | $1,000 | $1,000 | $1,000 |
| Retained earnings (deficit) | −$37.8M | −$33.1M | −$30.1M | −$25.7M | −$19.0M | −$14.8M |
| Accumulated other comprehensive income | $682,000 | $1.1M | $548,000 | $590,000 | $266,000 | $189,000 |
| Total shareholders' equity | −$24.9M | −$36.5M | −$34.1M | −$29.6M | −$23.3M | −$19.2M |
| Key figures | ||||||
| Total debt | $18.5M | $18.1M | $16.7M | $14.3M | $11.8M | $13.6M |
| Net cash (debt) | −$17.4M | −$18.0M | −$16.5M | −$13.4M | −$9.4M | −$9.4M |
| Working capital | −$19.3M | −$11.9M | −$12.4M | −$10.4M | −$3.6M | $443,000 |
| Tangible book value | −$24.9M | −$36.5M | −$34.1M | −$29.6M | −$23.3M | −$19.2M |
| Book value per share | −$0.34 | −$0.48 | −$0.45 | −$0.39 | −$0.31 | −$0.27 |
| Shares outstanding | 73.0M | 76.0M | 76.0M | 76.0M | 76.0M | 71.6M |
| Current ratio | 0.45 | 0.02 | 0.13 | 0.19 | 0.42 | 1.08 |
| Quick ratio | 0.42 | 0.01 | 0.01 | 0.06 | 0.38 | 0.73 |
| Equity / assets | −119.9% | −573.7% | −413.1% | −338.8% | −247.3% | −149.5% |
| Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | |
|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||
| Cash & short-term investments | $1.2M | $1.2M | $17.0M | $17.0M | $98,000 | $98,000 | $96,000 | $96,000 | $177,000 |
| Cash & equivalents | $1.2M | $1.2M | $135,000 | $132,000 | $98,000 | $98,000 | $96,000 | $96,000 | $177,000 |
| Short-term investments | — | — | $16.9M | $16.9M | — | — | — | — | $0 |
| Receivables | $13.5M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other current assets | $854,000 | $14.4M | $153,000 | $156,000 | $108,000 | $108,000 | $104,000 | $104,000 | $1.7M |
| Total current assets | $15.5M | $15.5M | $17.2M | $17.2M | $206,000 | $206,000 | $200,000 | $200,000 | $1.8M |
| Property, plant & equipment (net) | $5.2M | $3.2M | $5.5M | $3.5M | $3.2M | $3.2M | $3.3M | $3.3M | $3.5M |
| Goodwill & intangible assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-term investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other non-current assets | $6,000 | $2.1M | $15.0M | $17.1M | $3.0M | $3.0M | $2.9M | $2.9M | $2.9M |
| Total assets | $20.8M | $20.8M | $37.7M | $37.7M | $6.4M | $6.4M | $6.4M | $6.4M | $8.2M |
| Liabilities | |||||||||
| Accounts payable | $2,000 | $2,000 | $3,000 | $3,000 | $3,000 | $3,000 | $9,000 | $9,000 | $2,000 |
| Short-term debt | $8.4M | $8.4M | $22.9M | $22.9M | $7.4M | $7.4M | $7.6M | $7.6M | $8.1M |
| Total current liabilities | $34.8M | $34.8M | $27.6M | $27.6M | $12.1M | $12.1M | $11.9M | $11.9M | $14.3M |
| Long-term debt | $10.2M | $0 | $12.3M | $0 | $10.7M | $0 | $9.7M | $0 | $8.5M |
| Lease obligations | $107,000 | — | $138,000 | — | $175,000 | — | $238,000 | — | $199,000 |
| Other long-term liabilities | $713,999 | $10.9M | $20.3M | $32.6M | $20.1M | $30.8M | $19.8M | $29.4M | $19.5M |
| Total liabilities | $45.7M | $45.7M | $60.1M | $60.1M | $42.9M | $42.9M | $41.4M | $41.4M | $42.3M |
| Shareholders' equity | |||||||||
| Common stock & paid-in capital | $1,000 | $1,000 | $1,000 | $1,000 | $1,000 | $1,000 | $1,000 | $1,000 | $1,000 |
| Retained earnings (deficit) | −$37.8M | −$37.8M | −$34.3M | −$34.3M | −$33.1M | −$33.1M | −$31.4M | −$31.4M | −$30.1M |
| Accumulated other comprehensive income | $682,000 | $682,000 | −$38,000 | −$38,000 | $1.1M | $1.1M | $1.0M | $1.0M | $548,000 |
| Total shareholders' equity | −$24.9M | −$24.9M | −$22.5M | −$22.5M | −$36.5M | −$36.5M | −$34.9M | −$34.9M | −$34.1M |
| Key figures | |||||||||
| Total debt | $18.5M | $18.5M | $35.2M | $35.2M | $18.1M | $18.1M | $17.4M | $17.4M | $16.7M |
| Net cash (debt) | −$17.4M | −$17.4M | −$18.2M | −$18.2M | −$18.0M | −$18.0M | −$17.3M | −$17.3M | −$16.5M |
| Working capital | −$19.3M | −$19.3M | −$10.4M | −$10.4M | −$11.9M | −$11.9M | −$11.7M | −$11.7M | −$12.4M |
| Tangible book value | −$24.9M | −$24.9M | −$22.5M | −$22.5M | −$36.5M | −$36.5M | −$34.9M | −$34.9M | −$34.1M |
| Book value per share | −$0.34 | — | −$0.31 | — | — | — | — | — | — |
| Shares outstanding | 74.2M | — | 71.8M | — | — | — | — | — | — |
| Current ratio | 0.45 | 0.45 | 0.62 | 0.62 | 0.02 | 0.02 | 0.02 | 0.02 | 0.13 |
| Quick ratio | 0.42 | 0.03 | 0.62 | 0.62 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| Equity / assets | −119.9% | −119.9% | −59.7% | −59.7% | −573.7% | −573.7% | −542.3% | −542.3% | −413.1% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported (latest annual report filed December 31, 2025); data from EODHD.
MENS financial position
At the end of fiscal 2025 (December 31, 2025), Jyong Biotech had total assets of $20.8 million (up 226.4% from a year earlier), total liabilities of $45.7 million and shareholders' equity of -$24.9 million. It held $1.2 million in cash and short-term investments against $18.5 million of debt, net debt of $17.4 million. Its current ratio was 0.45.
Related: MENS income statement, MENS cash flow statement, MENS key metrics. See the MENS stock overview for the latest quote and news.
MENS balance sheet FAQ
What are Jyong Biotech's total assets?
Jyong Biotech reported total assets of $20.8 million at the end of fiscal 2025 (December 31, 2025), compared with $6.4 million a year earlier.
How much debt does Jyong Biotech have?
Jyong Biotech had $18.5 million of total debt at the end of fiscal 2025, including short-term borrowings and lease obligations. Its debt-to-equity ratio was —.
How much cash does Jyong Biotech have?
Jyong Biotech held $1.2 million in cash and short-term investments at the end of fiscal 2025; with $18.5 million of debt that is net debt of $17.4 million.
What is Jyong Biotech's book value?
Jyong Biotech's shareholders' equity (book value) was -$24.9 million at the end of fiscal 2025, or −$0.34 per share.
What is Jyong Biotech's current ratio?
Jyong Biotech had current assets of $15.5 million and current liabilities of $34.8 million, a current ratio of 0.45 (current liabilities exceed current assets).